Profil
Henri S.
Lichenstein was the founder of OrphAI Therapeutics, Inc. since 2013, serving as President & Chief Executive Officer until 2021.
Dr. Lichenstein is currently the Chief Executive Officer & Director at Shanghai Drug Farm Biological Technology Co., Ltd. since 2015.
Former positions include Vice President-Product Development at CuraGen Corp.
and Chief Development Officer at Topotarget A.
Postes actifs de Henri Lichenstein
| Sociétés | Poste | Début |
|---|---|---|
Shanghai Drug Farm Biological Technology Co., Ltd.
Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Develops IDInVivo technology for hepatitis B, cancer and autoimmune diseases | Directeur Général | 21/10/2015 |
Anciens postes connus de Henri Lichenstein
| Sociétés | Poste | Fin |
|---|---|---|
| TOPOTARGET A/S | Corporate Officer/Principal | - |
AI Therapeutics, Inc.
AI Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Directeur Général | 01/05/2021 |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology Develops protein, antibody and small molecule pharmaceutical products | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology Develops protein, antibody and small molecule pharmaceutical products | Health Technology |
Topotarget A/S
Topotarget A/S Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceuticals | Health Technology |
AI Therapeutics, Inc.
AI Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
Shanghai Drug Farm Biological Technology Co., Ltd.
Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Develops IDInVivo technology for hepatitis B, cancer and autoimmune diseases | Technology Services |
















